View this message in your internet browser.

Renal Anemia in Chronic Kidney Disease (CKD): Following the Omontys Recall

—A Webinar from Decision Resources Group

Join Decision Resources Group for a webinar on Renal Anemia in Chronic Kidney Disease (CKD): Following the Omontys Recall

This webinar will be presented two times:

Session I – Thursday April 25 at 10:00 AM EST
4:00 PM CET
Register Now!
Session II –Tuesday April 30 at 2:00 PM EST Register Now!

After nearly ten months on the U.S. market, Affymax/Takeda voluntarily recalled their once-monthly ESA Omontys (peginesatide) for dialysis patients on February 23, 2013 due to safety concerns. At the same time, there are several new products in the late stage clinical pipeline to treat renal anemia and iron deficiency. Additionally, there are new phosphate binders in development to not only treat bone and mineral metabolism imbalance, but to also potentially reduce the need for Erythropoiesis-Stimulating Agents (ESAs) and IV iron.

There are over 415,000 dialysis and 29 million CKD non-dialysis patients in the U.S. alone, creating a large potential for treatment therapies in this patient population. Many of these patients are treated for renal anemia and iron deficiency, with currently available agents: ESAs and IV iron. (Source: United States Renal Data System - 2012 Annual Data Report)

In this webinar DRG Director, Rob Dubman and Analyst, Matthew Scutcher, Ph.D., will provide an overview of the CKD market with a focus on renal anemia and address the following questions:

  • How large is the CKD market and how are patient populations defined?
  • How do treatment rates differ between ESAs, IV iron and phosphate binders, between CKD non-dialysis and dialysis, between US and Europe and other geographies?
  • What compounds are in the pipeline and how do physicians react to key compounds in development, with a focus on renal anemia?

A live Q&A session will be held following the presentation.

Please register by 8 a.m. U.S. Eastern Time on April 24 in order to attend the event.


About the Speakers

Rob DubmanRob Dubman is the director of nephrology at BioTrends Research Group. Prior to joining BioTrends, Mr. Dubman has worked in various market research roles within several biopharmaceuticals and medical device organizations, including Bristol-Myers Squibb (Oncology Therapeutics Network and medical imaging), Genzyme and Smith & Nephew. At Genzyme, Mr. Dubman managed many market research projects in Genzyme’s cardio-metabolic and renal business units. He has a Bachelor of Science degree from George Washington University and a Masters of Business Administration from Bentley University.

Matthew Scutcher, Ph.D.Matthew Scutcher, Ph.D., is a UK based analyst on Decision Resources BioPharma’s cardio, metabolic, and renal team. Prior to joining DR, he was a postdoctoral fellow in the department of bioengineering at Imperial College London, where he conducted research on the pulsatile shear stress responses of aortic endothelial cells. He earned his master’s degree in chemical engineering and chemical technology at Imperial College London and completed his doctorate in biochemical engineering at University College London, where he developed control systems for a vascular-tissue-engineering bioreactor designed to engineer coronary artery bypass grafts from bone-marrow-derived stem cells.

Decision Resources

kidneys

Products Included

  • Fibrogen/Astellas’s FG-4592/ASP1517
  • Akebia’s AKB-6548
  • Rockwell Medical’s Soluble Ferric Pyrophosphate
  • Keryx Pharmaceutical’s Zerenex
  • Vifor Pharmaceutical’s PA21


Webinar Details

Dates & Times

Session I
Thursday April 25 at
10:00 AM EST, 4:00 PM CET

Register Now!


Session II
Tuesday April 30 at 2:00 PM EST

Register Now!

Presentation: 45 minutes

Q & A: 15 minutes


Contact Us

Americas
JC Cherundolo
781-993-2750

Europe
Carla Donato
+32-2-357-06-15

Asia Pacific
Mariko Mitsuhashi
+81-5401-2615

Or contact us by email at sales@dresources.com







Fingertip Formulary



Terms of Use | Privacy Policy | Contact Us | Careers

Decision Resources Group • 8 New England Executive Park • Burlington, MA 01803

You are receiving this email because you have previously requested information from Decision Resources. If you wish to change your email preferences please click here.

© 2013 Decision Resources Group. All rights reserved.

Fingertip Formulary Abacus International HealthLeaders-InterStudy PharmaStrat Pinsonault Manhattan Research MRG AMR BioTrends Research Group Decision Resources DRG